Windlas Biotech Limited (WINDLAS) - Net Assets
Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has net assets worth Rs5.34 Billion INR (≈ $57.76 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs8.14 Billion ≈ $88.05 Million USD) and total liabilities (Rs2.80 Billion ≈ $30.29 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Windlas Biotech Limited tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs5.34 Billion |
| % of Total Assets | 65.6% |
| Annual Growth Rate | 22.09% |
| 5-Year Change | 154.0% |
| 10-Year Change | N/A |
| Growth Volatility | 34.42 |
Windlas Biotech Limited - Net Assets Trend (2018–2025)
This chart illustrates how Windlas Biotech Limited's net assets have evolved over time, based on quarterly financial data. See WINDLAS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Windlas Biotech Limited (2018–2025)
The table below shows the annual net assets of Windlas Biotech Limited from 2018 to 2025. For live valuation and market cap data, see WINDLAS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs5.06 Billion ≈ $54.70 Million |
+12.41% |
| 2024-03-31 | Rs4.50 Billion ≈ $48.66 Million |
+11.85% |
| 2023-03-31 | Rs4.02 Billion ≈ $43.50 Million |
+1.90% |
| 2022-03-31 | Rs3.95 Billion ≈ $42.69 Million |
+98.26% |
| 2021-03-31 | Rs1.99 Billion ≈ $21.53 Million |
-5.03% |
| 2020-03-31 | Rs2.10 Billion ≈ $22.67 Million |
+8.30% |
| 2019-03-31 | Rs1.94 Billion ≈ $20.94 Million |
+54.82% |
| 2018-03-31 | Rs1.25 Billion ≈ $13.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Windlas Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 707.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs2.75 Billion | 54.36% |
| Common Stock | Rs104.80 Million | 2.07% |
| Other Components | Rs2.20 Billion | 43.57% |
| Total Equity | Rs5.06 Billion | 100.00% |
Windlas Biotech Limited Competitors by Market Cap
The table below lists competitors of Windlas Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hester Biosciences Limited
NSE:HESTERBIO
|
$189.00 Million |
|
Humax Co. Ltd
KQ:115160
|
$189.07 Million |
|
Companhia Energética de Brasília - CEB
SA:CEBR3
|
$189.25 Million |
|
WW International, Inc. Common Stock
NASDAQ:WW
|
$189.35 Million |
|
Talisker Resources Ltd
TO:TSK
|
$188.87 Million |
|
Hocheng Corp
TW:1810
|
$188.78 Million |
|
Olimpo Real Estate SA
MC:YORE
|
$188.72 Million |
|
Amaero Ltd
AU:3DA
|
$188.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Windlas Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,499,360,000 to 5,057,720,000, a change of 558,360,000 (12.4%).
- Net income of 609,940,000 contributed positively to equity growth.
- Dividend payments of 114,950,000 reduced retained earnings.
- Other comprehensive income decreased equity by 189,700,000.
- Other factors increased equity by 253,070,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs609.94 Million | +12.06% |
| Dividends Paid | Rs114.95 Million | -2.27% |
| Other Comprehensive Income | Rs-189.70 Million | -3.75% |
| Other Changes | Rs253.07 Million | +5.0% |
| Total Change | Rs- | 12.41% |
Book Value vs Market Value Analysis
This analysis compares Windlas Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.91x to 3.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | Rs75.97 | Rs829.15 | x |
| 2019-03-31 | Rs88.82 | Rs829.15 | x |
| 2020-03-31 | Rs115.15 | Rs829.15 | x |
| 2021-03-31 | Rs109.36 | Rs829.15 | x |
| 2022-03-31 | Rs192.60 | Rs829.15 | x |
| 2023-03-31 | Rs185.93 | Rs829.15 | x |
| 2024-03-31 | Rs215.56 | Rs829.15 | x |
| 2025-03-31 | Rs239.64 | Rs829.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Windlas Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.06%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.03%
- • Asset Turnover: 1.00x
- • Equity Multiplier: 1.50x
- Recent ROE (12.06%) is below the historical average (12.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 8.96% | 3.18% | 1.21x | 2.32x | Rs-13.06 Million |
| 2019 | 32.97% | 20.91% | 1.02x | 1.54x | Rs444.63 Million |
| 2020 | 7.73% | 4.94% | 0.97x | 1.61x | Rs-47.53 Million |
| 2021 | 7.95% | 3.71% | 1.44x | 1.49x | Rs-40.80 Million |
| 2022 | 9.65% | 8.22% | 0.94x | 1.24x | Rs-13.89 Million |
| 2023 | 10.60% | 8.35% | 0.97x | 1.31x | Rs23.99 Million |
| 2024 | 12.93% | 9.25% | 1.00x | 1.39x | Rs131.93 Million |
| 2025 | 12.06% | 8.03% | 1.00x | 1.50x | Rs104.17 Million |
Industry Comparison
This section compares Windlas Biotech Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,320,289,591
- Average return on equity (ROE) among peers: 16.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Windlas Biotech Limited (WINDLAS) | Rs5.34 Billion | 8.96% | 0.52x | $189.00 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $1.33 Billion | 3.53% | 1.28x | $24.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.76 Billion | 12.24% | 2.47x | $366.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $626.77 Million |
| Abbott India Limited (ABBOTINDIA) | $8.33 Billion | 20.02% | 0.37x | $6.00 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $2.98 Billion | 25.93% | 1.18x | $4.16 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $30.64 Billion | 11.04% | 0.34x | $988.23 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.92 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $183.78 Million | 32.19% | 1.01x | $169.18 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $16.01 Billion | 44.99% | 0.54x | $1.59 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.69 Billion |
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more